This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): Selegiline transdermal system
Description: EMSAM is a selegiline transdermal system, irreversible monoamine oxidase B (MAO-B)inhibitor that, when applied to the skin, is designed to deliver selegiline continuously over a 24-hour period.
Deal Structure: In December 2004, Bristol-MyersSquibb Company and Somerset Pharmaceuticals, a joint venture between Mylan Laboratories and Watson Pharmaceuticals, announced they entered into an agreement for the commercialization and distribution of Somerset's EMSAM.
Under the terms of the agreement, Bristol-Myers Squibb receives exclusive distribution rights to commercialize EMSAM with an opportunity to negotiate, within a specified time frame,rights in any or all of the rest of the world. Financial terms were not disclosed, however, Somerset received an upfront payment and a further payment following regulatory approval in the U.S. In addition to the upfront payment, Somerset will receive milestone payments based on achievement of certain sales levels, as well as the reimbursement of certain developmentcosts incurred over the term of the agreement. Somerset will supply product to Bristol-Myers Squibb and receive royalties on Bristol-Myers Squibb sales of EMSAM.
In July 2008, Mylan acquired...See full deal structure in Biomedtracker
Pink Sheet Emsam still in the dark
Pink Sheet Somerset Emsam "not approvable"
Additional information available to subscribers only: